121 related articles for article (PubMed ID: 11821032)
1. Polyglutamation of a novel antifolate, MX-68, is not necessary for its anti-arthritic effect.
Urakawa K; Mihara M; Takagi N; Kawamura A; Akamatsu K; Takeda Y
Eur J Pharmacol; 2002 Jan; 435(2-3):237-44. PubMed ID: 11821032
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo biological activities of a novel nonpolyglutamable anti-folate, MX-68.
Mihara M; Urakawa K; Takagi N; Moriya Y; Takeda Y
Immunopharmacology; 1996 Oct; 35(1):41-6. PubMed ID: 8913793
[TBL] [Abstract][Full Text] [Related]
3. A novel non-polyglutamable anti-folate, MX-68, inhibits the induction of experimental autoimmune uveitis in rats.
Hiraoka M; Mihara M; Takeda Y; Miyasaka N
Exp Eye Res; 1998 Jul; 67(1):1-8. PubMed ID: 9702173
[TBL] [Abstract][Full Text] [Related]
4. Antirheumatic agents: novel methotrexate derivatives bearing a benzoxazine or benzothiazine moiety.
Matsuoka H; Ohi N; Mihara M; Suzuki H; Miyamoto K; Maruyama N; Tsuji K; Kato N; Akimoto T; Takeda Y; Yano K; Kuroki T
J Med Chem; 1997 Jan; 40(1):105-11. PubMed ID: 9016334
[TBL] [Abstract][Full Text] [Related]
5. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats.
Han YH; Kato Y; Watanabe Y; Terao K; Asoh Y; Sugiyama Y
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):394-400. PubMed ID: 11259322
[TBL] [Abstract][Full Text] [Related]
6. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects.
Urakawa K; Mihara M; Suzuki T; Kawamura A; Akamatsu K; Takeda Y; Kamatani N
Immunopharmacology; 2000 Jul; 48(2):137-44. PubMed ID: 10936511
[TBL] [Abstract][Full Text] [Related]
8. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68.
Montesinos MC; Desai A; Delano D; Chen JF; Fink JS; Jacobson MA; Cronstein BN
Arthritis Rheum; 2003 Jan; 48(1):240-7. PubMed ID: 12528125
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive properties of MX-68, a novel unpolyglutamatable antifolate.
Mihara M; Suzuki T; Kaneko E; Takagi N; Takeda Y
Biol Pharm Bull; 1997 Oct; 20(10):1071-5. PubMed ID: 9353567
[TBL] [Abstract][Full Text] [Related]
10. Preventive effect of a novel antifolate, MX-68, in murine systemic lupus erythematosus (SLE).
Mihara M; Takagi N; Urakawa K; Moriya Y; Takeda Y
Int J Immunopharmacol; 1997 Feb; 19(2):67-74. PubMed ID: 9278176
[TBL] [Abstract][Full Text] [Related]
11. Effect of MX-68 on airway inflammation and hyperresponsiveness in mice and guinea-pigs.
Nagao K; Akabane H; Masuda T; Komai M; Tanaka H; Nagai H
J Pharm Pharmacol; 2004 Feb; 56(2):187-96. PubMed ID: 15005877
[TBL] [Abstract][Full Text] [Related]
12. Antirheumatic agents. I. Novel methotrexate derivatives bearing an indoline moiety.
Matsuoka H; Kato N; Tsuji K; Maruyama N; Suzuki H; Mihara M; Takeda Y; Yano K
Chem Pharm Bull (Tokyo); 1996 Jul; 44(7):1332-7. PubMed ID: 8706140
[TBL] [Abstract][Full Text] [Related]
13. Computational predictions of binding affinities to dihydrofolate reductase: synthesis and biological evaluation of methotrexate analogues.
Graffner-Nordberg M; Marelius J; Ohlsson S; Persson A; Swedberg G; Andersson P; Andersson SE; Aqvist J; Hallberg A
J Med Chem; 2000 Oct; 43(21):3852-61. PubMed ID: 11052790
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts.
Asanuma H; Sanada S; Ogai A; Minamino T; Takashima S; Asakura M; Ogita H; Shinozaki Y; Mori H; Node K; Tomoike H; Hori M; Kitakaze M
J Cardiovasc Pharmacol; 2004 Apr; 43(4):574-9. PubMed ID: 15085069
[TBL] [Abstract][Full Text] [Related]
15. Polyglutamation of methotrexate. Is methotrexate a prodrug?
Chabner BA; Allegra CJ; Curt GA; Clendeninn NJ; Baram J; Koizumi S; Drake JC; Jolivet J
J Clin Invest; 1985 Sep; 76(3):907-12. PubMed ID: 2413074
[No Abstract] [Full Text] [Related]
16. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate suppresses passive adjuvant arthritis: studies on the metabolism of methotrexate in mononuclear cells derived from normal and adjuvant arthritic rats.
Ridge SC; Ferguson KM; Rath N; Galivan J; Freisheim JH; Oronsky AL; Kerwar SS
J Rheumatol; 1988 Aug; 15(8):1193-7. PubMed ID: 2460624
[TBL] [Abstract][Full Text] [Related]
18. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
19. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
Matherly LH; Barlowe CK; Goldman ID
Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
Li WW; Lin JT; Schweitzer BI; Bertino JR
Mol Pharmacol; 1991 Nov; 40(5):854-8. PubMed ID: 1719370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
